Ultragenyx Pharmaceutical Inc. (RARE) Free cash flow 2016–2025
Ultragenyx Pharmaceutical Inc. (RARE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$472.0MFY2025 · since FY2016: -$171.2M → -$472.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$472.0M | -12.1% |
| FY2024 | -$421.0M | +18.9% |
| FY2023 | -$519.0M | -4.5% |
| FY2022 | -$496.6M | -20.6% |
| FY2021 | -$411.8M | -133.8% |
| FY2020 | -$176.1M | +52.4% |
| FY2019 | -$370.2M | -25.6% |
| FY2018 | -$294.6M | -14.8% |
| FY2017 | -$256.6M | -49.9% |
| FY2016 | -$171.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice